Cell- and Single Molecule-Based Methods to Detect Anti-N-Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project

[1]  D. Bertrand,et al.  All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class , 2017, Molecular Psychiatry.

[2]  C. Geis,et al.  Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. , 2017, Physiological reviews.

[3]  P. McGuire,et al.  Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications , 2015, Psychopharmacology.

[4]  L. Tebartz van Elst,et al.  Immunological findings in psychotic syndromes: a tertiary care hospital's CSF sample of 180 patients , 2015, Front. Hum. Neurosci..

[5]  R. Dale,et al.  Autoantibodies in movement and psychiatric disorders: updated concepts in detection methods, pathogenicity, and CNS entry , 2015, Annals of the New York Academy of Sciences.

[6]  R. Kahn,et al.  Absence of N-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia: The Importance of Cross-Validation Studies. , 2015, JAMA psychiatry.

[7]  R. Dale,et al.  Antibodies to Surface Dopamine-2 Receptor and N-Methyl-D-Aspartate Receptor in the First Episode of Acute Psychosis in Children , 2015, Biological Psychiatry.

[8]  O. Vysata,et al.  Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia , 2015, Neuropsychiatric disease and treatment.

[9]  G. Spalletta,et al.  Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood–brain barrier integrity , 2014, Molecular Psychiatry.

[10]  G. Spalletta,et al.  Seroprevalence of autoantibodies against brain antigens in health and disease , 2014, Annals of neurology.

[11]  B. Bogerts,et al.  Seroprevalence of n-methyl-d-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients , 2014, European Archives of Psychiatry and Clinical Neuroscience.

[12]  A. David,et al.  Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis‡ , 2013, Psychological Medicine.

[13]  E. Bézard,et al.  Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors , 2013, Proceedings of the National Academy of Sciences.

[14]  J. Dalmau,et al.  Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis. , 2012, JAMA neurology.

[15]  G. Juckel,et al.  Investigation of antibodies against synaptic proteins in a cross-sectional cohort of psychotic patients , 2012, Schizophrenia Research.

[16]  F. Georges,et al.  Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. , 2012, Brain : a journal of neurology.

[17]  A. Duchemin,et al.  Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia , 2011, Schizophrenia Research.

[18]  R. Balice-Gordon,et al.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis , 2011, The Lancet Neurology.

[19]  Peter B. Jones,et al.  Disease-relevant autoantibodies in first episode schizophrenia , 2010, Journal of Neurology.

[20]  A. Vincent,et al.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia , 2010, Brain : a journal of neurology.

[21]  D. Choquet,et al.  Measurement and characteristics of neurotransmitter receptor surface trafficking (Review) , 2008, Molecular membrane biology.

[22]  Daniel Choquet,et al.  NMDA Receptor Surface Trafficking and Synaptic Subunit Composition Are Developmentally Regulated by the Extracellular Matrix Protein Reelin , 2007, The Journal of Neuroscience.

[23]  J. Honnorat,et al.  Effects of anti–glutamic acid decarboxylase antibodies associated with neurological diseases , 2007, Annals of neurology.

[24]  Paul J. Harrison,et al.  Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. , 2017, The lancet. Psychiatry.